Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR;Avaliação do metabolismo da glicose em pacientes acromegálicos antes e após tratamento com octreotide LAR

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 1, 2008, Pages 55-64

  Correa, Lívia L ^a,b   Taboada, Giselle F ^a   Van Haute, Flávia R ^a   Casini, Alessandra F ^a   Balarini, Giovanna A ^a,b   Neto, Leonardo Vieira ^a   Machado, Evelyn De O ^a   Fontes, Rosita ^b,c   De Andrade, Cláudia C ^c   Schrank, Yolanda ^b,c   Gadelha, Mónica R ^a,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^c Laboratorio Diagnosticos da America   (Brazil)

^d Rua Nascimento Silva   (Brazil)

Author keywords

Acromegaly; Glucose metabolism; Octreotide LAR

Indexed keywords

EID: 41149146140     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000100009     Document Type: Article

References (45)

1. Muggeo M, Robert S, Roth J, Kahn R. The insulin resistance in acromegaly: evidence for two alterations in the insulin tor on circulating monocytes. J Clin Endocrinol Metab. 1979; 48:17-25.
2. Gama R, Teale JD, Wright J, Ferns G, Marks V. Hyperproinsulinaemia in acromegaly: evidence for abnormal pancreatic beta-cell function. Ann Clin Biochem. 1997;34:627-31.
3. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986; 250:269-73.
4. Randle P, Garland P, Hales C, Newsholme E. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1:785-9.
5. Rosseti L, Frontoni S, Dimarchi R. Metabolic effects of IGF-I in diabetic rats. Diabetes. 1991; 40:444-8.
6. Boulware SD, Tamborlane WV, Rennet NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-l and insulin: dose-response relationships in healthy young and middle-aged adults. J Clin Invest. 1994;93:1131-9.
7. Yakar S, Liu JL, Fernandes AM, Wu Y, Schally AV, Frystyk J, et al. Liver-specific IGF-I gene delection leads to muscle insulin insensitivity. Diabetes. 2001;50 :1110-8.
8. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistence. Treat Endocrinol. 2005; 4:43-53.
9. Melmed S. Acromegaly, N Engl J Med. 1990; 322:966-77.
10. Ayuk J, Clayton RN, Holtder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613-7.
11. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferono D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000; 85:193-9.
12. Holdaway IM, Rajassorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004; 89:667-74.
13. Tamburrano G, Durante C, Baldelli R. Therapy of diabetes and dyslipidemia in acromegaly. Pituitary. 2002; 5:27-31.
14. Tavares EF, Dalbosco IS, Abucham J, Russo EM. True insulin and intact proinsulin levels in acromegalic patients. Eur J Endocrinol. 1996; 134:549-53.
15. Fredstorp L, Werner S, Bang P, Hall K. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with somatostatin analogue octreotide. Clin Endocrinol. 1994;41:495-501.
16. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab. 1992;75:1459-63.
17. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. J Clin Endocrinol Metab. 1991; 73:441-3.
18. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol. 1994; 130:581-6.
19. Elgin RG, Busby WH, Clemmons DR. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA. 1987; 84:3254-8.
20. Liu L, Brinkman A, Blat C, Harel L. IGFBP-1, an insulin-like growth factor binding protein, is a cell growth inibitor. Biochem Biophys Res Commun. 1991; 174:673-9.
21. Krejs GJ, Browne R, Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water and eletrolytes. Gastroenterology. 1980;78:26-31.
22. McKeage K, Cheer S, Wagstaff AJ. Octreotide Long-Acting Release (LAR) a review of its use in the management of acromegaly, Drugs. 2003; 63:2473-99,
23. Ipp BJ, Sinai Y, Bar-oz B. Somatostatin impairs clearance of exogenous insulin in humans. Diabetes. 1987; 36:673-7.
24. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006; 29:S43-8.
25. Turner RC, Holman RR, Matthews D, Hockaday TDR, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism. 1979; 28:1086-96.
26. Coutinho WF. Consenso latino- americano de obesidade. Arq Bras Endocrinol Metab. 1999; 43:21-67.
27. Donangelo I, Une K, Gadelha M. Diagnóstico e tratamento da acromegalia no Brasil, Arq Bras Endocrinol Metab. 2003; 47:331-46.
28. a ed, Rio de Janeiro: Guanabara Koogan AS; 2001, p.302-10.
29. Jallad RS, Musolino NRC, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a brazillan institution. Clin Endocrinol. 2005; 63:168-75.
30. Bengstsson BA, Brummer RJ, Edén S. Body composition in acromegaly. Clin Endocrinol. 1989; 31:481-90.
31. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, et al. Glucose homeostasis In acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol. 2003; 59:492-9.
32. Moller N, Schmitz O, Joorgensen JO, Astrup J, Back JF, Christensen SE, et al. Basal and insulin-stimulated substrate metabolism In patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992;74:1012-9.
33. Quabbe HJ, Plockinger U. Metabolic aspects of acromegaly and its treatment. Metabolism. 1996; 45:61-62.
34. Clemmons DR. Roles of insulin-like growth factor I and growth hormone in mediating insulin resistence in acromegaly. Pituitary. 2002; 5:181-3.
35. Hrebicek J, Janout V, Malincíková J, Horáková D, Cízek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab. 2002; 87:144-7.
36. Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, et al. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab. 2000; 85:147-54.
37. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest. 2003; 26:533-8.
38. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance In acromegaly. J Endocrinol Invest. 2002; 25:502-7.
39. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab. 2002; 87:1797-1804.
40. Hirose T, Kuroda T, Otsuki M, Takagi M, Yamamoto H, Motomura T, et al. A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide. Intern Med. 1997; 36:345-50.
41. Cantalamessa L, Catania A, Baldini M, Orsatti A. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient. Horm Metab Res. 1986; 18:790-1.
42. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol. 1992;36:271-9.
43. Vance ML, Harris AG. Long term treatment of 189 acromegalic patients with somatostatin analog octreotide. Arch Intern Med. 1991; 151:1573-8.
44. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients- a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol. 1995; 133:430-9.
45. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997; 82:2777-81.